Skip to main content
. 2023 Oct 26;109(9):2988–2997. doi: 10.3324/haematol.2023.283636

Figure 3.

Figure 3.

Clinical outcomes and the pattern of combinations of the top 6 chemotherapeutic agents used in the treatment of non-tuberculous mycobacterial infections in pediatric hematology/oncology patients. (A) Kaplan-Meier estimates of the overall survival (OS) rate in pediatric hematology/oncology patients with non-tuberculous mycobacterial (NTM) infection. The 5-year OS rate for all patients was 75.2% (95% confidence interval [CI]: 56-87) in the entire cohort. (B) Patients receiving hematopoietic stem cell transplantation (HSCT) had a 10-year OS rate of 59% (95% CI: 34-77, P=0.012 by log-rank test), whereas those who did not had no deaths from NTM infection. (C and D) Top 6 major antibiotic combinations used to treat NTM infection are summarized by UpSet plots. Panels depict drug combinations used to treat slow-growing mycobacteria (SGM; N=15) and rapid-growing mycobacteria (RGM; N=19), respectively. Each colored bar represents a different NTM species. Color codes are displayed in the right-hand column of each panel. INH: isoniazid; RBT: rifabutin; RFP: rifampicin; ST: sulfamethoxazole-trimethoprim. *M. avium, M. parascrofulaceum, and M. marseillense.